Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis

Wei Dong, Junming Bi, Hongwei Liu, Dong Yan, Qingqing He, Qianghua Zhou, Qiong Wang, Ruihui Xie, Yinjie Su, Meihua Yang, Tianxin Lin, and Jian Huang

Abstract
Background: Circular RNAs (circRNAs) have been considered to mediate occurrence and development of human cancers, generally acting as microRNA (miRNA) sponges to regulate downstream genes expression. However, the aberrant expression profile and dysfunction of circRNAs in human bladder cancer remain to be investigated. The present study aims to elucidate the potential role and molecular mechanism of circACVR2A in regulating the proliferation and metastasis of bladder cancer.

Methods: circACVR2A (hsa_circ_0001073) was identified by RNA-sequencing and validated by quantitative real-time polymerase chain reaction and agarose gel electrophoresis. The role of circACVR2A in bladder cancer was assessed both in vitro and in vivo. Biotin-coupled probe pull down assay, biotin-coupled microRNA capture, dual-luciferase reporter assay, and fluorescence in situ hybridization were conducted to evaluate the interaction between circACVR2A and microRNAs.

Results: The expression of circACVR2A was lower in bladder cancer tissues and cell lines. The down-regulation of circACVR2A was positively correlated with aggressive clinicopathological characteristics, and circACVR2A served as an independent risk factor for overall survival in bladder cancer patients after cystectomy. Our in vivo and in vitro data indicated that circACVR2A suppressed the proliferation, migration and invasion of bladder cancer cells. Mechanistically, we found that circACVR2A could directly interact with miR-626 and act as a miRNA sponge to regulate EYA4 expression.

Conclusions: circACVR2A functions as a tumor suppressor to inhibit bladder cancer cell proliferation and metastasis through miR-626/EYA4 axis, suggesting that circACVR2A is a potential prognostic biomarker and therapeutic target for bladder cancer.

Keywords: circACVR2A, miRNA-626, EYA4, Proliferation, Metastasis, Bladder cancer

Background
Bladder cancer (BC) ranks as the ninth most frequently-diagnosed cancer worldwide, and it’s the most common malignancy of urinary tract with high morbidity and mortality rates [1]. BC can be divided into two groups according to its distinct behavior: low-grade non-muscle-invasive bladder cancer (NMIBC) and high-grade muscle-invasive bladder cancer (MIBC). Although NMIBC is usually treatable by transurethral resection and intravesical therapy, it’s more likely to relapse and progress to MIBC [2]. MIBC frequently develops lymph node (LN) metastasis and distant metastasis and leads to poor prognosis [3]. Metastasis is life-threatening, and the 5-year survival rate is only 8.1% [4]. Nevertheless, there are no effective therapeutic methods for BC patients with tumor relapse or metastasis. Therefore, the molecular mechanisms that promote BC development and progression are essential for further study.

* Correspondence: lintx@mail.sysu.edu.cn; urolhj@sina.com
† Wei Dong, Junming Bi and Hongwei Liu contributed equally to this work.

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Circular RNAs (circRNAs) represent a novel class of non-coding RNAs characterized by a covalently closed loop without 5' cap and 3' polyadenylated tail [5], and they are derived from exon 'skipping' and 'direct back-splicing' of pre-mRNA transcripts [6]. Currently, with the development of bioinformatics analysis and high throughput sequencing, a plenty of circRNAs have been identified in mammalian cells [7–9]. Emerging evidence indicates that circRNAs are involved in the regulation of gene transcription and translation, and in the cytoplasm and nuclear localization of proteins, suggesting that they may participate in the progression of many diseases, including cancers. CircRNAs can function as microRNA (miRNA) sponges, RNA-binding protein sponges and protein-coding genes. For instance, ciRS-7 promotes colorectal cancer progression by blocking of tumor suppressive effects of miR-7 [10]. CircEPSTII affects triple-negative breast cancer proliferation and apoptosis through sponging miR-4753 and miR-6809 [11]. Circ-Foxo3 arrests CDK2 and blocks cell cycle progression by forming the circ-Foxo3-p21-CDK2 ternary complex [12]. Circ-Amotl1 reduces apoptosis and enhances cardiac repair by binding to PDK1 and AKT1, activating AKT phosphorylation and nuclear translocation [13]. Circ-ZNF609 is associated with heavy polysomes, and can be translated into a protein in a splicing-dependent and cap-independent manner [14]. An 87-amino-acid peptide encoded by the circular form of LINC-PINT directly interacts with polymerase associated factor complex (PAF1c) and suppresses the transcriptional elongation of multiple oncogenes of glioblastoma [15]. Recently, several circRNAs have been reported to be aberrantly expressed in BC cell lines and tissues, and they regulate proliferation, apoptosis, metastasis and epithelial-mesenchymal transition (EMT) [16–19]. However, the biological functions and clinical significance of circRNAs implicated in BC remain largely unknown.

In our present research, we identified a novel tumor suppressor circACVR2A from a published RNA sequencing (RNA-seq) data of human BC tissues and pair-matched normal bladder tissues, and verified the results using our established BC cell lines metastasis model [18, 20, 21]. We revealed that circACVR2A was derived from exons 3, 4 and 5 of the ACVR2A gene, and was significantly down-regulated in BC tissues and cell lines. BC patients with lower expression of circACVR2A were positively associated with advanced pathological stage, high grade, lymphatic metastasis and poorer survival. Furthermore, we demonstrated that circACVR2A could inhibit proliferation, migration and invasion of BC cells via binding to miR-626 as a miRNA sponge to regulate EYA4 expression. Therefore, circACVR2A may be a promising independent prognostic biomarker and potential target in BC therapy.

Methods
Patient tissue specimens
BC tissues and matched adjacent normal epithelial tissues were obtained from patients who underwent surgery at the Department of Urology of Sun Yat-sen Memorial Hospital (Guangzhou, China). All tissue specimens were immediately frozen in liquid nitrogen after surgical removal and stored at −80°C until RNA extraction. Histological and pathological diagnoses were independently confirmed by two experienced pathologists. The use of human BC tissue specimens was evaluated and approved by the Ethical Committee of Sun Yat-sen Memorial Hospital, and written informed consent was obtained from all patients.

Cell culture and treatments
Human BC cell lines T24, UM-UC-3, RT4, J82, 5637, HT-1376, TCCSUP and the immortalized normal uroepithelium cell line SV-HUC-1 were purchased from American Type Culture Collection (ATCC, USA). T24 and 5637 cells were cultured in RPMI-1640 (Gibco, Shanghai, China), RT4 cells were cultured in McCoy's 5A(Gibco), UM-UC-3, J82, HT-1376, TCCSUP and HEK-293 T cells were cultured in DMEM (Gibco), whereas SV-HUC-1 cells were maintained in F-12 K media (Gibco), supplemented with 10% FBS (Gibco, USA) and 1% penicillin/streptomycin (Gibco). Cells were grown in a humidified atmosphere of 5% CO2 at 37°C. For Actinomycin D assay, T24 and UM-UC-3 cells were exposed to 2 μg/mL Actinomycin D (Sigma, USA) to block transcription for 8, 16 and 24 h.

Nucleic acid preparation and quantitative real-time polymerase chain reaction (qRT-PCR)
Genomic DNA was isolated with MiniBEST Universal Genomic DNA Extraction Kit Ver.5.0 (Takara, Japan), and total RNA was isolated by using RNAiso Plus (Takara, Japan) according to the manufacturer's instructions. For RNase R digestion, 2 μg of total RNA was incubated for 30 min at 37°C with or without RNase R (3 U/μg) (Epicentre Technologies, USA), and the treated RNA was subsequently purified with the RNeasy MinElute Cleanup Kit (Qiagen, Germany). The nuclear and cytoplasmic fractions were extracted using a PARIS™ Kit (Life Technologies, USA) according to the manufacturer's protocol. cDNA was synthesized using the PrimeScript RT Reagent Kit (Takara, Japan), and RT-PCR was performed on a Quantstudio™ DX system (Applied Biosystems, Singapore) using TB Green Premix Ex Taq II (Takara, Japan). GAPDH and small nuclear U6 were used as internal controls. The sequence information of primers was listed in Additional file 1: Table S1.
Oligonucleotide transfection
Small interfering RNA (siRNA), miRNA mimics, miRNA inhibitors and negative control oligos were purchased from GenePharma (Shanghai, China). The sequences were listed in Additional file 2: Table S2. Cell transfection was conducted by using Lipofectamine RNAiMax (Life Technologies).

circRNA plasmid construction and stable transfection
Human circACVR2A cDNA was synthesized and cloned into the plenti-ciR-GFP-T2A vector (IGE Biotech Co, China) to construct overexpression plasmids. The constructs were confirmed by sequencing. Afterwards, plasmids were transfected into HEK293T cells to package lentivirus to infect T24 and UM-UC-3 cells. Cells were selected for 3 days with 2 μg/mL puromycin, and surviving cells were used as stable transfectants.

Cell proliferation, wound healing, migration and invasion assays
For cell viability detection, the MTS (Promega, USA) colorimetric assay was used according to the manufacturer’s protocol. The transfected cells were seeded in 96-well plates at a density of 2000 cells per well. Then absorbance was measured at a wavelength of 492 nm for 5 days using Spark 10 M (Tecan, Austria).

For colony formation assay, the transfected cells were seeded in 6-well plates at a density of 1000 cells per well. Approximately 10 days later, the clones were washed with 1x PBS, fixed with methanol and stained with 0.1% crystal violet. The clones were then imaged and quantified.

For wound healing assay, wounds were made using 200 μL pipette tips (time 0 h) in the middle of the six-well plates, and then the cells were cultured with serum-free medium immediately. After 12 h (for T24) or 24 h (for UM-UC-3), cell migration was photographed and the distance was measured and normalized to the 0 h control as the relative migration rate for comparison.

For transwell assay, chambers (8 μm pore size, Costar) with Matrigel (BD Science, USA) were used for cell invasion assays and chambers without Matrigel were used for cell migration assays. Approximately 5 x 10^4 cells were suspended in 200 μL serum-free medium and added to the upper chambers. A total of 600 μL of medium containing 10% FBS was placed into the lower chambers as a chemoattractant. After incubation for 8 h (for T24) and 20 h (for UM-UC-3), cells in the upper chamber were softly removed with cotton swabs and cells on the lower surface were fixed with methanol and stained with 0.1% crystal violet for photographing and counting.

Western blot analysis
Proteins were extracted using RIPA lysis buffer supplemented with 1% proteinase inhibitor and quantified by a BCA kit (Thermo, USA). Equal amounts of proteins (30 μg) were separated by 10% SDS–PAGE and transferred to PVDF membranes (Millipore, USA). After blocking for 1 h with 5% skim milk powder at room temperature, membranes were incubated with primary antibodies specific to EYA4(1:200, Santa Cruz, USA), ID2(1:500, Santa Cruz, USA) and GAPDH(1:5000, Abcam, UK) at 4 °C overnight. The membranes were then incubated with HRP conjugated goat anti-mouse secondary antibody (1:5000, Abcam, UK) and visualized using the Immobilon™ Western Chemiluminescent HRP Substrate (Millipore, USA).

Biotin-coupled probe pull-down assay
The pull-down assay was performed as previously described [20, 22]. In brief, the biotinylated circACVR2A probe and oligo probe (GenePharma, China) were incubated with M-280 Streptavidin magnetic beads (Invitrogen, USA) at room temperature for 2 h to generate probe-coated beads. Then approximately 1 x 10^7 BC cells were harvested, lysed, sonicated and incubated with probe-coated beads at 4°C overnight. After washing, the RNA complexes bound to the beads were eluted and extracted with RNeasy Mini Kit (Qiagen) and analyzed by qRT-PCR assay.

Biotin-coupled miRNA capture
Stably expressed circACVR2A BC cells were transfected with biotinylated miRNA mimics or nonsense control (GenePharma, China) using Lipofectamine RNAiMax (Life Technologies) and incubated for 48 h. M-280 streptavidin magnetic beads were washed with lysis buffer and blocked with yeast tRNA on a low speed rotator at 4°C for 2 h. The cells were harvested, lysed, sonicated and incubated with the blocked beads at 4°C overnight. The bound RNAs were purified using the RNeasy Mini Kit (Qiagen) and the abundance of circACVR2A in bound fractions was evaluated by qRT-PCR assay.

Fluorescence in situ hybridization (FISH)
The Cy3-labeled circACVR2A probe and Cy5-labeled miRNA-626 probe were designed and synthesized by GenePharma (Shanghai, China). The sequences of the probes were listed in Additional file 3: Table S3. The signals of the probe were detected by the Fluorescent In Situ Hybridization Kit (GenePharma, China) according to the manufacturer’s protocols. All images were acquired on ZEISS LSM800 Confocal Microscope system (Carl Zeiss AG, Germany).
**Luciferase reporter assay**

HEK293T cells (5 x 10^4) were seeded into 24-well plates and co-transfected with the corresponding psiCHECK™-2 vector and microRNA mimics. After incubation for 48 h, the firefly and Renilla luciferase activities were detected with a dual-luciferase reporter assay system (Promega, USA) according to the manufacturer's instructions. Relative luciferase activity was normalized to the firefly luciferase internal control. Independent experiments were performed in triplicate.

**Haematoxylin and eosin (HE) staining and immunohistochemistry (IHC) analysis**

This experiment was conducted as described previously [23, 24]. Primary antibodies specific for EYA4 (Santa Cruz, USA) and ID2 (Santa Cruz, USA) were used at the appropriate dilution in the experiments. Tissue samples of 5-μm thick paraffin section were stained with HE and IHC. Images were captured using a Nikon Eclipse 80i system with NIS-Elements software (Nikon, Japan).

**Animal experiments**

BALB/c nude mice (5–6 weeks old) were purchased from the Experimental Animal Center, Sun Yat-sen University. All of the animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-sen University and were performed in accordance with established guidelines. For tumor growth study, ten mice were included in each group, and stably expressed circACVR2A or control vector and microRNA mimics. After incubation for 48 h, the firefly and Renilla luciferase activities were detected with a dual-luciferase reporter assay system (Promega, USA) according to the manufacturer's instructions. Relative luciferase activity was normalized to the firefly luciferase internal control. Independent experiments were performed in triplicate.

**Statistical analysis**

Statistical analyses were conducted using SPSS19.0 (SPSS, Chicago, IL, USA) or GraphPad Prism7.0 (GraphPad Prism, Inc., La Jolla, CA, USA). Student's t test (two-tailed) was applied to assess the statistical significance between two groups. Chi-square test was used to analyze the correlation between circACVR2A expression levels and clinicopathological features in BC. Overall survival (OS) curves were calculated with the Kaplan-Meier method and analyzed with the log-rank test. Data were presented as the mean ± standard error of the mean (SEM). P < 0.05 was considered statistically significant.

**Results**

**Identification and characterization of circACVR2A in BC cells**

We firstly analyzed the published RNA-seq data of human BC tissues and paired normal bladder tissues [18] and found that circACVR2A was decreased in BC. We confirmed that circACVR2A expression was lower in highly invasive T24 and UM-UC-3 cell sublines than wild-type cells or higher in poorly invasive T24 and UM-UC-3 cell sublines than in wild-type cells using our previously established BC cell lines metastasis model [20, 21](Fig. 1a). Meanwhile, the expression of circACVR2A was significantly down-regulated in RT4, J82, 5637, UM-UC-3, T24, HT-1376 and TCCSUP BC cell lines, compared to the normal urothelial cell line SV-HUC-1(Fig. 1b). Since circRNAs don’t have 3’ polyadenylated tail, we detected the existence of circACVR2A in the reverse transcription products using random primers or oligo dT primers, and we verified that circACVR2A was almost undetectable when oligo-dT primers were used (Fig. 1c). Then, we designed divergent primers to amplify circACVR2A and convergent primers to amplify ACVR2A mRNA. CircACVR2A was only detectable in cDNA but not genomic DNA (gDNA) from T24 and UM-UC-3 cell lines by qRT-PCR with divergent primers, while ACVR2A could be amplified in both cDNA and gDNA using convergent primers (Fig. 1d). GAPDH was used as a control. Subsequently, Sanger sequencing of the qRT-PCR product of circACVR2A was performed to verify the head-to-tail splicing. The result was in accordance with circBase (http://circrna.org/), which indicated that circACVR2A was derived from exons 3, 4 and 5 of the ACVR2A gene (Fig. 1e).

Next, Actinomycin D assay demonstrated that the half-life of circACVR2A transcript exceeded 24 h, indicating that this isoform is more stable than the linear ACVR2A mRNA transcript in T24 and UM-UC-3 cells (Fig. 1f). Besides, RNase R digestion assay showed that the circular isoform was resistant to RNase R, whereas the linear isoform was obviously decreased after RNase R treatment (Fig. 1g). In addition, the subcellular localization of circACVR2A was detected with qRT-PCR analysis using nuclear and cytoplasmic fractions of T24 and UM-UC-3 cells and FISH assay. We found that circACVR2A was enriched in the cytoplasm fraction and mainly distributed in the cytoplasm (Fig. 1h-i). Taken together, these results indicated that circACVR2A was down-regulated in BC cell lines and was predominantly localized in the cytoplasm.
CircACVR2A suppresses proliferation, migration and invasion of BC cells in vitro

To investigate the potential biological effect of circACVR2A on BC cells, we established circACVR2A stably overexpressing cell lines via transfecting with circACVR2A vector. We also used RNA interference to silence the expression of circACVR2A in T24 and UM-UC-3 cells. The overexpression and knock-down...
efficiencies of circACVR2A were detected by qRT-PCR analysis (Fig. 2a, Additional file 4: Figure S1A). The expression level of ACVR2A was not affected by circACVR2A changes (Fig. 2b, Additional file 4: Figure S1B). Colony formation assay and MTS assay showed that overexpression of circACVR2A reduced the proliferation ability of T24 and UM-UC-3 cells (Fig. 2c-d). Simultaneously, wound healing assay revealed that overexpression of circACVR2A suppressed cell migration in T24 and UM-UC-3 cells. Accordantly, overexpression of circACVR2A also significantly inhibited BC cells migration and invasion in transwell migration and Matrigel invasion assays, respectively (Fig. 2e-g). In contrast, silencing circACVR2A promoted the proliferation, migration and invasion of BC cells (Additional file 4: Figure S1C-F). Taken together, these results suggested that circACVR2A...
functioned as a tumor suppressor via inhibiting proliferation, migration and invasion of BC cells in vitro.

**CircACVR2A serves as a miRNA sponge for miR-626 in BC cells**

Since circRNAs predominantly located in the cytoplasm were usually associated with miRNA sponging [25, 26], we further explored whether circACVR2A could bind to miRNAs. Eight potential target miRNAs (miR-548p, miR-571, miR-626, miR-659-3p, miR-1200, miR-1243, miR-1265, miR-1279) of circACVR2A were predicted by CircInteractome and miRanda, and these miRNAs were selected as candidate miRNAs for subsequent experiments (Fig. 3a). The positions of putative binding sites

---

**Fig. 3** CircACVR2A serves as a miR-626 sponge in BC cells.  
(a) Eight potential target miRNAs of circACVR2A were predicted by CircInteractome and miRanda.  
(b) Schematic model showed the putative binding sites of eight miRNA candidates associated with circACVR2A.  
(c) Relative levels of circACVR2A in T24 and UM-UC-3 lysates after RNA pull down using circACVR2A probe or oligo probe.  
(d) Relative levels of eight miRNAs in T24 and UM-UC-3 lysates pulled down by circACVR2A probe or oligo probe.  
(e) Relative levels of circACVR2A in T24 and UM-UC-3 lysates captured by biotinylated wild-type miRNA-626 (Biotin-miR-626-wt) or mutant miR-626 (Biotin-miR-626-mut).  
(f) Luciferase reporter assay in HEK293T cells co-transfected with miRNA mimics, psiCHECK-2-wild type circACVR2A (circACVR2A-wt) or psiCHECK-2-mutant type circACVR2A (circACVR2A-mut) plasmids.  
(g) Schematic of circACVR2A wild-type (wt) and mutant (mut) luciferase reporter vectors.  
(h) FISH showed the co-localization between circACVR2A and miR-626 in T24 cells. Nuclei were stained with DAPI. CircACVR2A was labeled with Cy3 and miR-626 was labeled with Cy5.
in circACVR2A were shown in Fig. 3b. The biotinylated circACVR2A probe and oligo probe were designed and were applied to perform RNA pull-down assay. The pull-down efficiency was verified in T24 and UM-UC-3 cells transfected with circACVR2A or vector (Fig. 3c). The miRNAs pulled down by biotinylated probes were purified and analyzed by qRT-PCR. Among the eight candidate miRNAs, only miR-626 could be abundantly pulled down by circACVR2A probe in both T24 and UM-UC-3 cells (Fig. 3d).

To further confirm the sponge effect between circACVR2A and miR-626, we conducted biotin-coupled miRNA capture assay, luciferase reporter assay and FISH. T24 and UM-UC-3 cells stably overexpressing circACVR2A were transfected with biotin-labeled miR-626 (biotin-miR-626-wt) or its mutant (biotin-miR-626-mut), and circACVR2A captured by miR-626 was evaluated by qRT-PCR. We found that the enrichment of circACVR2A in the captured fraction was much higher in biotin-miR-626-wt group than in biotin-miR-626-mut group (Fig. 3e), indicating that miR-626 could also bind to circACVR2A. Meanwhile, the sequence of wild-type circACVR2A or the sequence with mutant miR-626 binding sites was inserted into psiCHECK-2 vector to perform luciferase reporter assays. After co-transfection with miRNA mimics and psiCHECK-2 vector for 48 h in HEK293T cells, the Rluc activity was detected. Up-regulation of miR-626 mimics and psiCHECK-2 vector containing wild-type or mutant version of EYA4 3′ untranslated region (3′UTR). The Rluc activity was obviously reduced in HEK293T cells co-transfected with mir-626 mimics and EYA4-wt 3′UTR vector, but the Rluc activity was not distinctly changed in HEK293T cells co-transfected with miR-626 mimics and the mutant vector (Fig. 4g-h). Accordingly, Western blot analysis indicated that the expression of EYA4 protein was significantly decreased after transfection of miR-626 mimics, whereas EYA4 was up-regulated after transfection of miR-626 inhibitor in T24 and UM-UC-3 cells (Fig. 4i, Additional file 5: Figure S2E). Meanwhile, the expression level of ID2, a negative regulated downstream gene of EYA4 [29], had the opposite change compared to EYA4 level (Fig. 4i, Additional file 5: Figure S2E).

Previous studies have demonstrated that EYA4 acts as a tumor suppressor gene in non-small cell lung cancer [30], colorectal cancer [31], hepatocellular carcinoma [32], esophageal squamous cell carcinoma [33] and pancreatic ductal adenocarcinoma [29], but the biological role of EYA4 in BC remains unknown. Therefore, we designed two siRNAs targeting EYA4 to evaluate its influence on BC cells. Subsequent MTS assay and colony formation assay revealed that silencing of EYA4 promotes the growth of T24 and UM-UC-3 cells (Fig. 5a-b), and wound healing assay indicated that cell migration ability of BC cells transfected with EYA4 siRNAs was enhanced (Fig. 5c). In addition, down-regulation of EYA4 facilitated cell migration and invasion abilities assessed by transwell migration and matrigel invasion assays (Fig. 5d). These results showed that EYA4 exerted an anti-tumor effect on BC cells. Taken together, these data indicated that miR-626 promoted proliferation, migration and invasion of BC cells by targeting EYA4.

We applied miRDB [27] and TargetScan [28] to identify the possible target genes of miR-626 in BC cells, and found that EYA4 could be a candidate target gene of miR-626. To testify this finding, we conducted luciferase reporter assays using psiCHECK-2 vector containing wild-type or mutant version of EYA4 3′ untranslated region (3′UTR). The Rluc activity was obviously reduced in HEK293T cells co-transfected with miR-626 mimics and EYA4-wt 3′UTR vector, but the Rluc activity was not distinctly changed in HEK293T cells co-transfected with miR-626 mimics and the mutant vector (Fig. 4g-h). Accordingly, Western blot analysis indicated that the expression of EYA4 protein was significantly decreased after transfection of miR-626 mimics, whereas EYA4 was up-regulated after transfection of miR-626 inhibitor in T24 and UM-UC-3 cells (Fig. 4i, Additional file 5: Figure S2E). Meanwhile, the expression level of ID2, a negative regulated downstream gene of EYA4 [29], had the opposite change compared to EYA4 level (Fig. 4i, Additional file 5: Figure S2E).

miR-626 is up-regulated and exerts an oncogenic role by targeting EYA4 in BC cells

Then, we evaluated the expression level and potential role of miR-626 in BC cells based on the association between circACVR2A and miR-626. The expression level of miR-626 was detected by qRT-PCR, and we found that miR-626 was obviously up-regulated in BC cell lines compared with SV-HUC-1 (Fig. 4a). Afterwards, we assessed the functional effect of miR-626 in T24 and UM-UC-3 cells by transfecting miRNA mimics and miRNA inhibitor. Cell proliferation, migration and invasion abilities were significantly promoted in BC cells transfected with miR-626 mimics as compared to the mimics NC group (Fig. 4b-f). On the contrary, inhibiting miR-626 significantly suppressed proliferation, migration and invasion capabilities of BC cells by transfecting miR-626 inhibitor (Additional file 5: Figure S2A and D).

CircACVR2A abrogates the oncogenic effect of miR-626 in BC cells

Furthermore, rescue experiments were performed by co-transfecting circACVR2A and miR-626 mimics in BC cells to estimate whether circACVR2A exerts the tumor-suppressing effect on BC cells via sponging miR-626. We found that the colony formation ability of BC cells co-transfected with miR-626 mimics and circACVR2A was reduced compared with that of BC cells transfected only with miR-626 mimics, suggesting that overexpression of circACVR2A could partly
abolish the enhancement of proliferation induced by miR-626 (Fig. 6a). Similarly, up-regulation of circACVR2A could also partly attenuate the miR-626 mediated promotion of migration and invasion in T24 and UM-UC-3 cells (Fig. 6b-c). Meanwhile, Western blot assay indicated that the EYA4 protein level was partly increased in BC cells co-transfected with miR-626 mimics and circACVR2A compared to BC cells transfected only with miR-626 mimics, while the ID2 protein level showed the opposite response (Fig. 6d-e). Collectively, these results
demonstrated that circACVR2A inhibited BC cells progression partly through impairing the oncogenic role of miR-626.

**CirACVR2A inhibits tumor growth and lymphatic metastasis in vivo**

To further investigate the effect of circACVR2A on tumor growth in vivo, UM-UC-3 cells stably transfected with circACVR2A or control vector were subcutaneously injected into BALB/c nude mice. The tumor volume and weight were significantly decreased in the circACVR2A overexpressing group compared with those of the vector group (Fig. 7a-b, Additional file 6: Figure S3A and B). IHC analysis was applied to detect the protein expression of EYA4 and ID2 in xenografted tumors of each group. The expression of EYA4 was obviously increased, while the
ID2 expression level was remarkably reduced in tumor tissues of circACVR2A overexpressing group (Fig. 7c). Moreover, we also transfected firefly luciferase into UM-UC-3 cells previously constructed for xenograft, and those cells were injected into the footpads of nude mice. We found that the bioluminescence of popliteal LNs was weak or undetectable, and the volumes of popliteal LNs were obviously decreased in circACVR2A stably overexpressing group, suggesting that up-regulation of circACVR2A could suppress lymphatic metastasis of BC in vivo. (Fig. 7d-f, Additional file 6: Figure S3C).

CircACVR2A is down-regulated in BC and associated with prognosis of BC patients

We firstly applied qRT-PCR to detect the expression of circACVR2A in 50 pairs of BC tissues and matched...
Overexpression of circACVR2A inhibits the growth and metastasis of BC cells in vivo. a-b UM-UC-3 cells stably transfected with circACVR2A or vector were injected subcutaneously into the left dorsum of BALB/c nude mice. Tumor volume and weight were dramatically decreased in circACVR2A overexpressing group. c HE staining and IHC analysis of EYA4 and ID2 expression in subcutaneous xenograft tumors. Overexpression of circACVR2A could up-regulate EYA4 and down-regulate ID2 expression. d Bioluminescence of the popliteal LNs was detected by an in vivo bioluminescence imaging system. e Popliteal LNs were enucleated and measured. The volume of popliteal LNs was significantly decreased in circACVR2A overexpressing group. f Representative images of HE staining analysis of the popliteal LNs in each group.
adjacent normal tissues. We found that circACVR2A was significantly down-regulated in BC tissues compared with adjacent normal tissues (Fig. 8a). Subsequently, the expression of circACVR2A was evaluated in 140 cases of BC patients with complete survival data and clinical characteristics, and the results indicated that patients with advanced pathological T stage, high grade, positive lymphatic metastasis had low levels of circACVR2A, whereas other clinicopathological features were not significantly correlated with the expression of circACVR2A (Table 1). Furthermore, Kaplan-Meier analysis demonstrated that patients with low expression of circACVR2A were remarkably associated with poor OS (Fig. 8b).

Discussion
Currently, an increasing number of circRNAs have been identified by means of bioinformatics analysis and high-throughput sequencing. Since circRNAs possess the regulatory potency of gene expression [7], and have been proven to be potential promising biomarkers [34], a large number of circRNAs have been investigated in the development and progression of different cancers [10, 11, 15, 35, 36], including BC [16–18, 20]. However, the functions of circRNAs in BC remain largely unknown, and still need to be further explored. In this study, we identified a new circRNA, circACVR2A, originating from exons 3, 4 and 5 of its host gene.
ACVR2A, that was down-regulated in T24 and UM-UC-3 cells and further decreased in our established highly invasive cell sublines [20]. Overexpression of circACVR2A significantly suppressed proliferation, migration and invasion of BC cells, whereas siRNA-mediated silencing of circACVR2A had the opposite effects on BC cells.

Accumulating studies have implied that circRNAs mainly act as miRNA sponges to exert various biological roles [26, 34, 37], thereby regulating downstream target genes. As the most well-known circRNA, ciRS-7 contains multiple miR-7 binding sites and decreases the biological effect of miR-7 on its target genes via sponging miR-7 [10, 26, 38]. In addition, emerging evidence has shown that the cytoplasmic localization of circRNA is closely associated with miRNA sponging [25, 26]. In our study, nuclear and cytoplasmic fractions assays and FISH confirmed that circACVR2A was predominantly distributed in the cytoplasm. Then, we verified that circACVR2A could interact with miR-626 in BC cells by biotinylated RNA pull-down and dual-luciferase reporter assays. We subsequently assessed the functional effects of miR-626 by transfecting miR-626 mimics or inhibitor into BC cells, and found that miR-626 exerted an oncogenic role on BC. Furthermore, overexpression of circACVR2A antagonized miR-626-mediated enhancement of cell proliferation, migration and invasion in BC cells. These results suggested that circACVR2A could serve as a miRNA sponge for miR-626.

Previous study has demonstrated that miRNAs can post-transcriptionally reduce the levels of specific target protein coding gene expression by binding to the 3'UTR of target mRNAs and resulting in translation inhibition or mRNA degradation [39]. Recent evidence indicates that circRNAs regulate gene expression by directly binding to miRNAs to prevent them from interacting with target genes [11, 18–20, 36]. In our study, EYA4 was predicted as the candidate target gene of miR-626 by miRDB and Targetscan, and was further testified by dual-luciferase reporter assay. Although several studies have shown that EYA4 acts as a tumor suppressor gene in some tumors [29–32], its association with BC has not been described. Therefore, our present study provided additional information to understand the biological function of EYA4 in BC cells. Moreover, we detected the expression of ID2, which has been identified as a negative regulated downstream gene of EYA4 [29]. The changes in ID2 expression suggested that it may be an oncogene in BC, which was consistent with a previous report [40].

Recent studies have indicated that circRNAs play a crucial role in the progression and prognosis of human cancer [37, 41]. The involvement of circRNAs in BC has been investigated in several studies. For instance, circPRMT5 promotes metastasis of BC through sponging miR-30c to induce EMT, and up-regulated expression of circPRMT5 was positively correlated with advanced stage and worse survival in BC patients [19]. Circ-ITCH inhibits BC progression by sponging miR-17/miR-224, and BC patients with low circ-ITCH had shortened survival [42]. In our study, we demonstrated that low expression of circACVR2A was associated with advanced pathological T stage, high grade, lymphatic metastasis and poor survival.

### Conclusions

In summary, our present study demonstrated that circACVR2A was down-regulated in BC cell lines and tissues, and its low expression was associated with poor clinicopathological characteristics of BC patients. Mechanistically, circACVR2A could significantly inhibit proliferation and metastasis of BC through directly binding to miR-626 and subsequently reduce the suppressing capability of miR-626 on EYA4, as shown in Fig. 8c. Our study suggested that circACVR2A was a novel potential prognostic biomarker and therapeutic target in BC.

### Table 1

| Characteristics | circACVR2A expression | p value |
|-----------------|-----------------------|---------|
| Age(years)      |                       |         |
| < 65            | 72(51.4)              | 0.557   |
| ≥ 65            | 68(48.6)              |         |
| Gender          |                       | 0.399   |
| Male            | 103(73.6)             |         |
| Female          | 37(26.4)              |         |
| Pathology stage |                       | 0.016*  |
| pTa-pT1         | 60(42.9)              |         |
| pT2-pT4         | 80(57.1)              |         |
| Grade           |                       | 0.038*  |
| Low             | 23(16.4)              |         |
| High            | 117(83.6)             |         |
| Tumor size(cm)  |                       | 0.591   |
| < 3             | 118(84.3)             |         |
| ≥3              | 22(15.7)              |         |
| Lymph nodes metastasis |          | 0.036*  |
| Negative        | 109(77.9)             |         |
| Positive        | 31(22.1)              |         |
| Total           | 140                   | 38      | 102    |

*p < 0.05 was considered to be statistically significant (chi-square test)"

### Additional files

**Additional file 1:** Table S1. The primers used in this study. (DOCX 14 kb)

**Additional file 2:** Table S2. The oligonucleotides transfected in this study. (DOCX 13 kb)
Additional file 3: Table S3. The probes used in this study. (DOCX 13 kb)

Additional file 4: Figure S1. CircACVR2A silencing promotes proliferation, migration and invasion of BC cells in vitro. (A-B) qRT-PCR analysis of circACVR2A and ACVR2A mRNA in T24 and UM-UC-3 cells after transfected with circACVR2A siRNAs. (C-D) Cell proliferation ability of T24 and UM-UC-3 cells transfected with circACVR2A siRNAs was evaluated by colony formation assay and MTS assay. (E) Cell migration capability of T24 and UM-UC-3 cells transfected with circACVR2A siRNAs was assessed by wound healing assays. (F) The influence on cell migration and invasion abilities of T24 and UM-UC-3 cells transfected with circACVR2A siRNAs was evaluated by transwell migration and matrigel invasion assay, respectively. (TIF 6721 kb)

Additional file 5: Figure S2. miRNA-626 exerts oncogenic effects on BC cells by targeting EYA4 in vitro. (A-B) Cell proliferation ability of T24 and UM-UC-3 cells transfected with inhibitor NC or miR-626 inhibitor was decreased using MTS assay and colony formation assay. (C) Cell migration capability of T24 and UM-UC-3 cells transfected with inhibitor NC or miR-626 inhibitor was suppressed using wound healing assays. (D) Cell migration and invasion abilities of T24 and UM-UC-3 cells transfected with inhibitor NC or miR-626 inhibitor were reduced using transwell migration and matrigel invasion assays. (E) Western blot analysis indicated that miR-626 could down-regulate EYA4 and up-regulate ID2 expression in BC cells. (TIF 5359 kb)

Additional file 6: Figure S3. Overexpression of circACVR2A suppresses the growth and metastasis of BC cells in vivo. (A-B) Tumor volume and weight were obviously decreased in circACVR2A overexpressing group. (C) The volume of popliteal LNs was significantly reduced in circACVR2A overexpressing group. (TIF 4305 kb)

Abbreviations

UTR: 3′ untranslated region; ACVR2A: Activin A receptor type 2A; BC: Bladder cancer; circRNAs: circular RNAs; EMT: Epithelial-mesenchymal transition; EYA4: EYA transcriptional coactivator and phosphatase 4; ID2: Inhibitor of DNA binding 2; LN: Lymph node; qRT-PCR: Quantitative real-time polymerase chain reaction

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (Grant No. 81825016, 81772719, 81772728,81572719, 81472384), National Natural Science Foundation of Guangdong (Grant No. 2015A0303110111), Science and Technology Program of Guangdong (Grant No. 2018A030310041, 201604020156, 201604020177), the Science and Technology Planning Project of Guangdong Province (Grant No.2017B020227007), Guangdong Special Support Program (2017TX0246), Project Supported by Guangdong Province Higher Vocational Colleges & Schools Pearl River Scholar Funded Scheme (for Tianxin Lin).

Availability of data and materials

The RNA-seq data of human BC tissues and normal bladder tissues analyzed in this study were included in the uploaded GEO dataset (GSE97239) of this published article (https://doi.org/10.15252/embr.201643581). The rest of datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WD, HWL and JMB conceived and designed the study. QO, QW, YJS and YD performed the experiments. MMY, HQZ and RXH performed the data analysis. WD, TXL and JH wrote and reviewed the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The current study was approved by the Ethical Committee of Sun Yat-sen Memorial Hospital and the Institutional Animal Care and Use Committee of Sun Yat-sen University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China. 2Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107th Yanjiangxi Road, Guangzhou, China.

Received: 16 January 2019 Accepted: 2 May 2019
Published online: 17 May 2019

References

1. Antoni S, Ferlay J, Soejomotarama I, Znaor A, Jemal A, Bray F. Bladder Cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108.
2. Zuiveloon TC, Nieuweboer AJ, Vekomy H, Kinkel WS, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol. 2012;61:2:128–45.
3. Karnat AM, Hahn NM, Elsaithiaou J, Lerner SP, Malmstrom PU, Choi W, et al. Bladder cancer. Lancet. 2013;38:21:296–810.
4. Abdollah F, Gandaglia G, Thuret R, Schmoges T, Tian Z, Jeldes C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37:219–25.
5. Wilson JE, Sharp PA. Molecular biology. A circuitous route to noncoding RNA. Science. 2013;34:0:440–1.
6. Ashwal-Fluss R, Meyer M, Pampaduri NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014;565–66.
7. Memczak S, Jens M, Elefsoinioi A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
8. Salzman J, Chen RE, Olsen MN, Wang PL, Brown PO. Cell-type specific features of circular RNA expression. PLoS Genet. 2013;9:e1003777.
9. Jeck WR, Sorrentino JA, Wang K, Stevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with AUU repeats. RNA. 2013;19:141–57.
10. Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, et al. circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics. 2018;8:4003–15.
11. Wu W, Wei Q, Toden S, Yoshida K, Nagasaka T, Fujiwara T, et al. Circular RNA ciRS-7—a promising prognostic biomarker and a potential therapeutic target in colorectal Cancer. Clin Cancer Res. 2017;23:3918–28.
12. Chacko RE, Dobrovic A, Souter J, Gilchrist A, Keden R, Kavanagh M, et al. Incidence of oral cancer. Cancer. 2013;118:723–31.
13. Zhang Z, Liu J, Zhu C, Zhang J, Tang J, Tao J, et al. circHIPK3 sponges miR-183-5p and promotes prostate cancer cell proliferation and migration by targeting miR-183-5p. Cell Death Disc. 2018;25:2495–507.
14. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018;9:4475.
15. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in Myogenesis. Mol Cell. 2017;66:22–37 e9.
16. Zhong J, Zhang Z, Zhang Z, Qian S, Tao D, Zheng F, et al. A circular RNA, circHIPK3, sponges miR-558 to suppress hepanererase expression in bladder cancer cells. EMBO Rep. 2017;18:1646–59.
19. Chen X, Chen RX, Wei WS, Li YH, Feng ZH, Tan L, et al. PRMT5 circular RNA promotes metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce epithelial-mesenchymal transition. Clin Cancer Res. 2018;24:6319-30.

20. Liu H, Bi J, Dong W, Yang M, Shi J, Jiang N, et al. Invasion-related circular RNA circFNDC3B inhibits bladder cancer progression through the miR-1178-3p/G3BP2/SRC/FAK axis. Mol Cancer. 2018;17:161.

21. Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, et al. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010;6:e1000879.

22. Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. 2016;37:2602–11.

23. Chen X, Gu P, Xie R, Han J, Liu H, Wang B, et al. Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer. J Cell Mol Med. 2017;21:1266–79.

24. He W, Zhong G, Jiang N, Wang B, Fan X, Chen C, et al. Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis. J Clin Invest. 2018;128:861–75.

25. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–11.

26. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.

27. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146–52.

28. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian miRNAs. eLife. 2015;4:e05005.

29. Mo SJ, Liu X, Hao XY, Chen W, Zhang KS, Cai JP, et al. EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through beta-catenin/I2 pathway. Cancer Lett. 2016;380:403–12.

30. Wilson IM, Vucic EA, Enfield KS, Thu KL, Zhang YA, Chari R, et al. EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene. 2014;33:4464–73.

31. Kim SJ, Tae CH, Hong SN, Min BH, Chang DK, Rhee PL, et al. EYA4 acts as a new tumor suppressor gene in colorectal Cancer. Mol Carcinog. 2015;54:1748–57.

32. Mo SJ, Hou X, Hao XY, Cai JP, Liu X, Chen W, et al. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-kappaB-dependent RAP1 transactivation. Cancer Commun. 2018;389.

33. Luo M, Li Y, Shi X, Yang W, Zhou F, Sun N, et al. Ablent methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Cancer Sci. 2018;109:1811–24.

34. Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.

35. Qiu M, Xia W, Chen R, Wang S, Xu Y, Ma Z, et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res. 2018;78:2839–51.

36. Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151–64.

37. Zhong YX, Du YJ, Yang X, Mo YZ, Fan CM, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79.

38. Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018;9:417.

39. Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20–51.

40. Luo M, Li ZW, Wang W, Zeng YG, Liu ZH, Qiu JX. Upregulated H19 contributes to bladder cancer cell proliferation by regulating ID2 expression. FEBS J. 2013;280:1709–16.

41. Yang ZZ, Xie L, Han L, Qu X, Yang YH, Zhang Y, et al. Circular RNAs: regulators of Cancer-related signaling pathways and potential diagnostic biomarkers for human cancers. Theranostics. 2017;7:3105–19.

42. Yang CD, Yuan WB, Yang X, Li P, Wang JZ, Han J, et al. Circular RNA circITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018;17:19.